Citations

Mayo Clinic

Clear

236 citation(s) found for "Xu, Xiong".

Delayed hepatocellular carcinoma model for end‐stage liver disease exception score improves disparity in access to liver transplant in the United States
Hirose, Ryutaro , Stock, Peter G. , Schladt, David P., Xiong, Hui , Liu, Jiannong , Olthoff, Kim M. , Harper, Ann, Kasiske, Bertram L. , Kim, W. Ray , Heimbach, Julie K. , Snyder, Jon J. , Israni, Ajay K.

Hepatology | January 16, 2015 | Volume: 61 | Issue: 5 | Pages: 1643-1650

10.1002/hep.27704 | PMID 25644186 Get It

The current system granting liver transplant candidates with hepatocellular carcinoma (HCC) additional Model for End‐Stage Liver Disease (MELD) points is controversial due to geographic disparity and uncertainty regarding optimal prioritization of candidates. The current national policy assigns a MELD exception score of 22 immediately upon listing of eligible patients with HCC. The aim of this study was to evaluate the potential effects of delays in granting these exception points on transplant rates for HCC and non‐HCC patients. We used Scientific Registry of Transplant Recipients data and liver simulated allocation modeling software and modeled (1) a 3‐month delay before granting a MELD exception score of 25, (2) a 6‐month delay before granting a score of 28, and (3) a 9‐month delay before granting a score of 29. Of all candidates waitlisted between January 1 and December 31, 2010 (n = 28,053), 2773 (9.9%) had an HCC MELD exception. For HCC candidates, transplant rates would be 108.7, 65.0, 44.2, and 33.6 per 100 person‐years for the current policy and for 3‐, 6‐, and 9‐month delays, respectively. Corresponding rates would be 30.1, 32.5, 33.9, and 34.8 for non‐HCC candidates. Conclusion: A delay of 6‐9 months would eliminate the geographic variability in the discrepancy between HCC and non‐HCC transplant rates under current policy and may allow for more equal access to transplant for all candidates. (Hepatology 2015;61:1643–1650)
Krüppel-like factor KLF10 regulates transforming growth factor receptor II expression and TGF-β signaling in CD8+ T lymphocytes
Papadakis, Konstantinos A. , Krempski, James , Reiter, Jesse, Svingen, Phyllis A., Xiong, Yuning, Sarmento, Olga F., Kelcher, April M. Huseby , Johnson, Aaron J. , Lomberk, Gwen , Faubion, William A. , Svingen, Phyllis, Huseby, April, Lomberk, Gwen A, Urrutia, Raul A, Johnson, Aaron J. , Urrutia, Raúl , Lomberk, Gwen L , Kelcher, April M H , Krempski, James W

American Journal of Physiology-Cell Physiology | December 4, 2014 | Volume: 308 | Issue: 5 | Pages: C362-C371

10.1152/ajpcell.00262.2014 | PMID 25472963 Get It

KLF10 has recently elicited significant attention as a transcriptional regulator of transforming growth factor-β1 (TGF-β1) signaling in CD4+ T cells. In the current study, we demonstrate a novel role for KLF10 in the regulation of TGF-β receptor II (TGF-βRII) expression with functional relevance in antiviral immune response. Specifically, we show that KLF10-deficient mice have an increased number of effector/memory CD8+ T cells, display higher levels of the T helper type 1 cell-associated transcription factor T-bet, and produce more IFN-γ following in vitro stimulation. In addition, KLF10−/− CD8+ T cells show enhanced proliferation in vitro and homeostatic proliferation in vivo. Freshly isolated CD8+ T cells from the spleen of adult mice express lower levels of surface TGF-βRII (TβRII). Congruently, in vitro activation of KLF10-deficient CD8+ T cells upregulate TGF-βRII to a lesser extent compared with wild-type (WT) CD8+ T cells, which results in attenuated Smad2 phosphorylation following TGF-β1 stimulation compared with WT CD8+ T cells. Moreover, we demonstrate that KLF10 directly binds to the TGF-βRII promoter in T cells, leading to enhanced gene expression. In vivo viral infection with Daniel's strain Theiler's murine encephalomyelitis virus (TMEV) also led to lower expression of TGF-βRII among viral-specific KLF10−/− CD8+ T cells and a higher percentage of IFN-γ-producing CD8+ T cells in the spleen. Collectively, our data reveal a critical role for KLF10 in the transcriptional activation of TGF-βRII in CD8+ T cells. Thus, KLF10 regulation of TGF-βRII in this cell subset may likely play a critical role in viral and tumor immune responses for which the integrity of the TGF-β1/TGF-βRII signaling pathway is crucial.
Differential coupling of KLF10 to Sin3-HDAC and PCAF regulates the inducibility of the FOXP3 gene
Xiong, Yuning, Svingen, Phyllis A., Sarmento, Olga O., Smyrk, Thomas C. , Dave, Maneesh, Khanna, Sahil , Lomberk, Gwen , Faubion, William A. , Lomberk, Gwen A, Urrutia, Raul A, Sarmento, Olga F., Urrutia, Raúl , Lomberk, Gwen L

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology | June 19, 2014 | Volume: 307 | Issue: 6 | Pages: R608-R620

10.1152/ajpregu.00085.2014 | PMID 24944246 Get It

Inducible gene expression, which requires chromatin remodeling on gene promoters, underlies the epigenetically inherited differentiation program of most immune cells. However, chromatin-mediated mechanisms that underlie these events in T regulatory cells remain to be fully characterized. Here, we report that inducibility of FOXP3, a key transcription factor for the development of T regulatory cells, depends upon Kruppel-like factor 10 (KLF10) interacting with two antagonistic histone-modifying systems. We utilized chromatin immunoprecipitation, genome-integrated reporter assays, and functional domain KLF10 mutant proteins, to characterize reciprocal interactions between this transcription factor and either the Sin3-histone deacetylase complex or the histone acetyltransferase, p300/CBP-associated factor (PCAF). We characterize a Sin3-interacting repressor domain on the NH2 terminus of KLF10, which works to limit the activating function of this transcription factor. Indeed, inactivation of this Sin3-interacting domain renders KLF10 able to physically associate with PCAF as to induce FOXP3 gene transcription. We show that this biochemical data derived from studying our genome-integrated reporter cell system are recapitulated in primary murine lymphocytes. Collectively, these results advance our understanding of how a single transcription factor, namely KLF10, functions as a toggle to integrate antagonistic signals regulating FOXP3 and, thus, immune activation.
Insulin‐like growth factor‐1 regulates the SIRT 1‐p53 pathway in cellular senescence
Tran, Duc T. , Zhang, Haibo , He, Hanbing, Wang, Yang , Li, Qintong , Kirkland, James L. , Bergholz, Johann S. , Zhang, Yujun , Xiao, Zhi‐Xiong Jim

Aging Cell | April 30, 2014 | Volume: 13 | Issue: 4 | Pages: 669-678

10.1111/acel.12219 | PMID 25070626 Get It

Summary Cellular senescence, which is known to halt proliferation of aged and stressed cells, plays a key role against cancer development and is also closely associated with organismal aging. While increased insulin‐like growth factor ( IGF ) signaling induces cell proliferation, survival and cancer progression, disrupted IGF signaling is known to enhance longevity concomitantly with delay in aging processes. The molecular mechanisms involved in the regulation of aging by IGF signaling and whether IGF regulates cellular senescence are still poorly understood. In this study, we demonstrate that IGF ‐1 exerts a dual function in promoting cell proliferation as well as cellular senescence. While acute IGF ‐1 exposure promotes cell proliferation and is opposed by p53, prolonged IGF ‐1 treatment induces premature cellular senescence in a p53‐dependent manner. We show that prolonged IGF ‐1 treatment inhibits SIRT 1 deacetylase activity, resulting in increased p53 acetylation as well as p53 stabilization and activation, thus leading to premature cellular senescence. In addition, either expression of SIRT 1 or inhibition of p53 prevented IGF ‐1‐induced premature cellular senescence. Together, these findings suggest that p53 acts as a molecular switch in monitoring IGF ‐1‐induced proliferation and premature senescence, and suggest a possible molecular connection involving IGF ‐1‐ SIRT 1‐p53 signaling in cellular senescence and aging.
Forkhead Box P3 Regulates TLR10 Expression in Human T Regulatory Cells
Bell, Michael P., Svingen, Phyllis A., Rahman, Meher K., Xiong, Yuning, Faubion, William A.

The Journal of Immunology | April 18, 2014 | Volume: 179 | Issue: 3 | Pages: 1893-1900

10.4049/jimmunol.179.3.1893 | PMID 17641056 Get It

Abstract Although functionally relevant TLRs can be expressed on human T regulatory (Treg) cells, little is known about the transcriptional control of their expression. We hypothesized that the transcription factor forkhead box P3 (FOXP3) regulates the expression of TLR family members in human Treg cells. Using primary human T cells and a reporter assay in Jurkat T cell lines, we dissected the regulation of TLR10, a TLR highly expressed in human Treg cells. We determined that TLR10 was expressed in human Treg cells through quantitative PCR, Western blotting, and flow cytometry. DNA binding of FOXP3 to a suspected cis-regulatory region in proximity to the transcription start site of TLR10 was established through EMSA and chromatin immunoprecipitation. Transcriptional control of TLR10 by FOXP3 was determined through luciferase reporter assays in Jurkat T cell lines. Relevance of FOXP3 to TLR10 gene transcription in primary T cells was established through the transfection of primary CD4+CD25−FOXP3− T cells with a FOXP3 expression vector, which resulted in prompt production of TLR10 mRNA. Enhanced expression of TLR10 protein in primary Treg cells was induced in a calcium-dependent fashion through TCR activation. The suspected promotional cooperation between FOXP3 and NF-AT was established in the abolition of the luciferase signal upon transfection of a mutant FOXP3 devoid of NF-AT-binding activity. These results suggest that human Treg cells express TLR10, and this expression is regulated through a cooperative complex of FOXP3 and NF-AT.
Exome Sequencing Identifies a Novel FOXP3 Mutation in a 2‐Generation Family With Inflammatory Bowel Disease
Okou, David T. , Mondal, Kajari , Faubion, William A. , Kobrynski, Lisa , Denson, Lee A. , Mullé, Jennifer G. , Xiong, Yuning, Svingen, Phyllis A., Bose, Promita, Waters, Jon, Cutler, David J. , Ramachandran, Dhanya , Patel, Viren , Prahalad, Sampath , Zwick, Michael E. , Kugathasan, Subra

Journal of Pediatric Gastroenterology and Nutrition | January 14, 2014 | Volume: 58 | Issue: 5 | Pages: 561-568

10.1097/mpg.0000000000000302 | PMID 24792626 Get It

ABSTRACTObjectives:Inflammatory bowel disease (IBD) is heritable, but a total of 163 variants commonly implicated in IBD pathogenesis account for only 25% of the heritability. Rare, highly penetrant genetic variants may also explain mendelian forms of IBD and some of the missing heritability. To test the hypothesis that rare loss‐of‐function mutations can be causative, we performed whole exome sequencing (WES) on 5 members of a 2‐generation family of European ancestry presenting with an early‐onset and atypical form of IBD.Methods:WES was performed for all of the 5 family members; the mother and 3 male offspring were affected, whereas the father was unaffected. Mapping, annotation, and filtering criteria were used to reduce candidate variants. For functional testing we performed forkhead box P3 (FOXP3) staining and a T‐cell suppression assay.Results:We identified a novel missense variant in exon 6 of the X‐linked FOXP3 gene. The c.694A>C substitution in FOXP3 results in a cysteine‐to‐glycine change at the protein position 232 that is completely conserved among all vertebrates. This variant (heterozygous in the mother and hemizygous in all 3 affected sons) did not impair FOXP3 protein expression, but significantly reduced the ability of the host's T regulatory cells to suppress an inappropriate autoimmune response. The variant results in a milder immune dysregulation, polyendocrinopathy, enteropathy, and X‐linked phenotype with early‐onset IBD.Conclusions:Our study illustrates the successful application of WES for making a definitive molecular diagnosis in a case of multiply affected families, with atypical IBD‐like phenotype. Our results also have important implications for disease biology and disease‐directed therapeutic development.
Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease
Benzinger, Tammie L.S. , Blazey, Tyler , Xiong, Chengjie , Raichle, Marcus E. , Ances, Beau M. , Bateman, Randall J. , Cairns, Nigel J., Fagan, Anne M. , Goate, Alison , Marcus, Daniel S. , Aisen, Paul, Christensen, Jon, Ercole, Lindsay, Hornbeck, Russ C. , Farrar, Angela, Aldea, Patricia, Jasielec, Mateusz S., Owen, Christopher J. , Xie, Xianyun, Mayeux, Richard , Klunk, William E. , Mathis, Chester A. , Ringman, John M. , Thompson, Paul M. , Saykin, Andrew J. , Johnson, Keith A. , Salloway, Stephen , Correia, Stephen , Schofield, Peter R. , Masters, Colin L. , Villemagne, Victor L. , Martins, Ralph N. , Ourselin, Sébastien , Rossor, Martin N. , Fox, Nick C. , Cash, David M. , Weiner, Michael W. , Buckles, Virginia, Moulder, Krista L., Morris, John C. , Jack, Clifford R. , Koeppe, Robert A. , Su, Yi , Xiong, Chengjie , Snyder, Abraham Z. , Brickman, Adam M. , McDade, Eric , Ghetti, Bernardino , Sperling, Reisa Anne , Rowe, Christopher Cleon , Holtzman, David M. , Saykin, Andrew J , Schofield, Peter R , Thompson, Paul M , Bateman, Randall J , Masters, Colin L , Benzinger, Tammie L S , Ances, Beau M , Fox, Nick C , Morris, John C , Cash, David M , Goate, Alison M

Proceedings of the National Academy of Sciences | November 5, 2013 | Volume: 110 | Issue: 47 | Pages: No page available

10.1073/pnas.1317918110 | PMID 24194552 Get It

Significance Beta-amyloid plaque accumulation, glucose hypometabolism, and neuronal atrophy are hallmarks of Alzheimer’s disease. However, the regional ordering of these biomarkers prior to dementia remains untested. In a cohort with Alzheimer’s disease mutations, we performed an integrated whole-brain analysis of three major imaging techniques: amyloid PET, [ 18 F]fluro-deoxyglucose PET, and structural MRI. We found that most gray-matter structures with amyloid plaques later have hypometabolism followed by atrophy. Critically, however, not all regions lose metabolic function, and not all regions atrophy, even when there is significant amyloid deposition. These regional disparities have important implications for clinical trials of disease-modifying therapies.